Results 61 to 70 of about 5,328 (181)
Cancer Medicine, Volume 15, Issue 2, February 2026.Survival outcomes in gradual/local progression group were superior to dramatic progression group; survival period of dramatic progression group who received chemotherapy was longer than that of other therapies. ROS1 kinase domain mutations were detected predominantly in dramatic progression group, whereas activation of bypass and downstream pathways ...
Quan‐Quan Tan +10 more
wiley +1 more source
Molecular MedicineBackground Fibrosis cataract occurs in patients receiving cataract extraction. Still, no medication that can cure the disease exists in clinical. This study aims to investigate the effects and mechanisms of Entrectinib on fibrotic cataract in vitro and ...
Xuefei Ding +8 more
doaj +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.ABSTRACT A high number of poorly soluble compounds are being developed; thus, understanding the factors that influence their absorption is critical. Intestinal bile salts, which facilitate micelle‐mediated solubilization, are particularly important for drugs with low solubility and are reported to be highly variable.
Laura G. Al‐Amiry Santos +2 more
wiley +1 more source
Case Reports in Oncology, 2023 Introduction: C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1–2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known to be effective against ...
Hiromune Sawada +12 more
doaj +1 more source
Targeting ALK and WIP1 : neuroblastoma precision medicine under development [PDF]
, 2022 Neuroblastoma is the childhood solid tumor accountable for the largest number of deaths, calling for improved treatment. Some genetic alterations are considered crucial in driving initiation and progression of neuroblastoma.
Treis, Diana
core +1 more source
NSUN5 as a Prognostic Biomarker Correlates with Malignant Phenotype and Therapeutic Target in Glioma
Brain and Behavior, Volume 16, Issue 1, January 2026.This study systematically analyzed the expression levels, clinical features, prognostic value, immune‐related roles, drug sensitivity, and biological functions of NSUN5 in glioma based on the CGGA and TCGA databases. Finally, a machine learning‐based prognostic model was constructed, and the function of NSUN5 was validated through in vitro experiments.
Ye Wenhao +10 more
wiley +1 more source
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. [PDF]
, 2019 Advanced non-small cell lung cancer (NSCLC) is a complex disease comprising molecularly distinct tumor types, each with a unique biology that is becoming increasingly better characterized.
Abdel Karim, Nagla, Kelly, Karen
core
Melanoma: Pathogenesis and Targeted Therapy
MedComm, Volume 7, Issue 1, January 2026.The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu +5 more
wiley +1 more source
Case Reports in Oncology, 2023 Introduction: The burden of melanoma is increasing globally. Despite the use of immunotherapy and targeted therapy, the prognosis of metastatic melanoma remains relatively poor.
Shaheenah Dawood, Zulfaqqar Jaffar Ali
doaj +1 more source
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling [PDF]
, 2018 To accurately recapitulate the heterogeneity of human diseases, animal models require to recreate multiple complex genetic alterations. Here, we combine the RCAS-TVA system with the CRISPR-Cas9 genome editing tools for precise modeling of human tumors ...
Almeida Marques, Carolina +9 more
core +3 more sources